Tiziana Life Sciences is trading at $1.04 (7.5% up) in pre-market, extending its sharp recovery following the significant selloff on July 24.
- The upward move is attributed to dip-buying interest and a generally supportive, risk-on tone in U.S. equity futures, with no fresh company-specific catalysts reported.
- This marks the third consecutive positive session for the stock, signaling short-term recovery momentum rather than a shift in fundamental news.